Thromb Haemost 1984; 52(01): 034-036
DOI: 10.1055/s-0038-1661131
Original Article
Schattauer GmbH Stuttgart

Evaluation of Dose and Route Effects of Platelet Activating Factor-Induced Extravasation in the Guinea Pig

Authors

  • Dean A Handley

    The Platelet Section, Sandoz Research Institute, East Hanover, New Jersey, U.S.A.
  • Ronald G Van Valen

    The Platelet Section, Sandoz Research Institute, East Hanover, New Jersey, U.S.A.
  • Mary Kay Melden

    The Platelet Section, Sandoz Research Institute, East Hanover, New Jersey, U.S.A.
  • Robert N Saunders

    The Platelet Section, Sandoz Research Institute, East Hanover, New Jersey, U.S.A.
Further Information

Publication History

Received 14 March 1984

Accepted 05 May 1984

Publication Date:
19 July 2018 (online)

Preview

Summary

Platelet-activating factor (PAF) is a naturally occurring lipid that is reported to induce vessel hyperpermeability leading to loss of protein-rich plasma (extravasation). We have quantitated the systemic extravasation effects of synthetic PAF in the guinea pig by monitoring increases in hematocrit. When given intravenously (10-170 ng/kg), PAF produced dose-dependent increases in hematocrit, with maximal hemoconcentration developing in 5-7 min. In leukopenic animals the expected hematocrit increase was reduced by 57%. PAF given intra-arterially produced the dose-dependent changes in hematocrit similar to the intravenous effects of PAF. However, PAF given intraperitoneally (10-2500 μg/kg) was 800-1100-fold less effective than the other routes and hemoconcentration continued for 30-45 min until a maximal hematocrit was observed. These results show that PAF may markedly influence extravasation of plasma in a dose and route-dependent manner.